Appendix

Reslizumab has just been assigned a permanent J code (J 2786). However, an average sales price (ASP) has yet to emerge from the marketplace. During the interim, a temporary J code is being used (unclassified biologic). It is expected that an ASP will emerge around Spring 2018, at which time we will provide an updated reimbursement range/number. It should be noted that there is a price differential for the reimbursement received for a temporary J code (typically based on the price of acquisition) versus that for a permanent J code.